Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012)

International Journal of Antimicrobial Agents

Volumn 43, Issue 6, 2014, Pages 533-539

  Farrell, David J ^a   Sader, Helio S ^a   Flamm, Robert K ^a   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

Author keywords

Ceftolozane tazobactam; Nosocomial; Pneumonia; Surveillance

Indexed keywords

AMIKACIN; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEFTOLOZANE; CEFTOLOZANE PLUS TAZOBACTAM; CEPHALOSPORIN; COLISTIN; COTRIMOXAZOLE; DORIPENEM; GENTAMICIN; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TAZOBACTAM; TIGECYCLINE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID;

ACINETOBACTER; ARTICLE; BACTERIAL PNEUMONIA; BACTERIUM ISOLATE; CONTROLLED STUDY; ENTEROBACTERIACEAE; EUROPE; GRAM NEGATIVE BACTERIUM; HOSPITAL PATIENT; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STENOTROPHOMONAS MALTOPHILIA; UNITED STATES; UNIVERSITY HOSPITAL; ANALOGS AND DERIVATIVES; CROSS INFECTION; DRUG EFFECTS; GRAM NEGATIVE INFECTION; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ACADEMIC MEDICAL CENTERS; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CROSS INFECTION; EUROPE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PNEUMONIA, BACTERIAL; UNITED STATES;

EID: 84902087476     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2014.01.032     Document Type: Article

References (28)

1. D.M. Livermore, S. Mushtaq, Y. Ge, and M. Warner Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates Int J Antimicrob Agents 34 2009 402 406
2. C.G. Giske, J. Ge, and P. Nordmann Activity of cephalosporin CXA-101 (FR264205) and comparators against extended-spectrum-β-lactamase-producing Pseudomonas aeruginosa J Antimicrob Chemother 64 2009 430 431
3. B. Moya, L. Zamorano, C. Juan, J.L. Pérez, Y. Ge, and A. Oliver Activity of a new cephalosporin, CXA-101 (FR264205), against β-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients Antimicrob Agents Chemother 54 2010 1213 1217
4. B. Moya, L. Zamorano, C. Juan, Y. Ge, and A. Oliver Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa Antimicrob Agents Chemother 54 2010 3933 3937
5. S. Takeda, Y. Ishii, K. Hatano, K. Tateda, and K. Yamaguchi Stability of FR264205 against AmpC β-lactamase of Pseudomonas aeruginosa Int J Antimicrob Agents 30 2007 443 445 (Pubitemid 47498958)
6. H.S. Sader, P.R. Rhomberg, D.J. Farrell, and R.N. Jones Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes Antimicrob Agents Chemother 55 2011 2390 2394
7. E. Titelman, I.M. Karlsson, Y. Ge, and C.G. Giske In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae Diagn Microbiol Infect Dis 70 2011 137 141
8. C.C. Bulik, P.R. Tessier, R.A. Keel, C.A. Sutherland, and D.P. Nicolau In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse Gram-negative organisms Antimicrob Agents Chemother 56 2012 544 549
9. D.M. Livermore, S. Mushtaq, and Y. Ge Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus β-lactamase- producing Enterobacteriaceae J Antimicrob Chemother 65 2010 1972 1974
10. A. Sorbello, S. Komo, T. Valappil, and S. Nambiar Registration trials of antibacterial drugs for the treatment of nosocomial pneumonia Clin Infect Dis 51 2010 S36 S41
11. M. Iregui, S. Ward, G. Sherman, V.J. Fraser, and M.H. Kollef Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia Chest 122 2002 262 268 (Pubitemid 34754172)
12. Clinical and Laboratory Standards Institute Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard 9th ed. 2012 CLSI Wayne, PA [Document M07-A9]
13. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing: twenty-third informational supplement 2013 CLSI Wayne, PA [Document M100-S23]
14. A.P. Magiorakos, A. Srinivasan, R.B. Carey, Y. Carmeli, M.E. Falagas, and C.G. Giske et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance Clin Microbiol Infect 18 2012 268 281
15. European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of MICs and zone diameters. Version 3.1, February 2013 2013 EUCAST http://www.eucast.org/clinical-breakpoints/ [accessed August 2013]
16. Wyeth Pharmaceuticals Inc. Tygacil® package insert 2012 Wyeth Philadelphia, PA http://www.tygacil.com [accessed January 2013]
17. R.N. Jones Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia Clin Infect Dis 51 2010 S81 S87
18. S.T. Micek, A.E. Lloyd, D.J. Ritchie, R.M. Reichley, V.J. Fraser, and M.H. Kollef Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment Antimicrob Agents Chemother 49 2005 1306 1311 (Pubitemid 40463352)
19. H.W. Boucher, G.H. Talbot, D.K. Benjamin Jr., J. Bradley, R.J. Guidos, and R.N. Jones et al. 10 × 20 progress - development of new drugs active against Gram-negative bacilli: an update from the Infectious Diseases Society of America Clin Infect Dis 56 2013 1685 1694
20. D.M. Livermore Of Pseudomonas, porins, pumps and carbapenems J Antimicrob Chemother 47 2001 247 250 (Pubitemid 32229565)
21. G.M. Rossolini Acquired metallo-β-lactamases: an increasing clinical threat Clin Infect Dis 41 2005 1557 1558 (Pubitemid 41691592)
22. E. Riera, G. Cabot, X. Mulet, M. García-Castillo, R. del Campo, and C. Juan et al. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem J Antimicrob Chemother 66 2011 2022 2027
23. C.G. Giske, L. Buaro, A. Sundsfjord, and B. Wretlind Alterations of porin, pumps, and penicillin-binding proteins in carbapenem resistant clinical isolates of Pseudomonas aeruginosa Microb Drug Resist 14 2008 23 30 (Pubitemid 351441848)
24. O. Samuelsen, M.A. Toleman, A. Sundsfjord, J. Rydberg, T.M. Leegaard, and M. Walder et al. Molecular epidemiology of metallo-β-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion Antimicrob Agents Chemother 54 2010 346 352
25. G. Chandorkar, J.A. Huntington, M.H. Gotfried, K.A. Rodvold, and O. Umeh Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects J Antimicrob Chemother 67 2012 2463 2469
26. W.A. Craig, and D.R. Andes In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice Antimicrob Agents Chemother 57 2013 1577 1582
27. B. Miller, E. Hershberger, D. Benziger, M. Trinh, and I. Friedland Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses Antimicrob Agents Chemother 56 2012 3086 3091
28. B. VanScoy, R.E. Mendes, A.M. Nicasio, M. Castanheira, C.C. Bulik, and O.O. Okusanya et al. Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model Antimicrob Agents Chemother 57 2013 2809 2814